BioSpace News Archive

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”) today announced the appointment of Timothy L. Moore to its board of directors, increasing board membership to six.

Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference.

Evogene Ltd. today reported the receipt of a formal notification from The Nasdaq Stock Market LLC (" Nasdaq ") that the Company has regained compliance with Listing Rule 5450(a)(1), which requires the Company’s ordinary shares to maintain a minimum bid price of $1.00 per share.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, is proud to be certified by Great Place to Work® for the second consecutive year.

Fresenius Medical Care North America’s (FMCNA) Renal Therapies Group today announced the availability of Speedswap ® , a new option for the NxStage ® System One ™ with NxView ™ that enables the changing of a flow-compromised dialysis filter without replacing the entire cartridge.

Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, today announced it has raised $10M in Series B funding led by VCapital.

Society for Science (the Society) and Thermo Fisher Scientific Inc., the world leader in serving science, today announced that Thermo Fisher will be the new title sponsor of the Society’s middle school STEM (science, technology, engineering and math) competition, the nation’s premier STEM competition.

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today it has signed a twelve month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine.

Athos Therapeutics, Inc. (“Athos”) is a late-stage preclinical biotech company using Artificial Intelligence (AI) to develop small molecule therapeutics for immune-mediated diseases and cancer.

Frontier Medicines Corporation today announced the appointment of Mark Dizon, J.D., to the position of general counsel.